Osteonecrosis of the jaw (ONJ) is a well-documented adverse effect associated with
bisphosphonate therapy. Nonetheless, recently, other antiresorptive and antiangiogenic
medications have also been implicated in ONJ. Previous case studies have reported
ONJ in patients with exposure to denosumab (an inhibitor of receptor activator of
nuclear factor κ B ligand), bevacizumab (a vascular endothelial growth factor inhibitor),
and sunitinib (a tyrosine kinase inhibitor that targets vascular endothelial growth
factor receptors among others). We report 5 patients with no known history of bisphosphonate
administration who displayed clinical findings consistent with ONJ.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2014 Published by Elsevier Inc.
